其他
Landos Biopharma(LABP)04-16 05:25
$Landos Biopharma(LABP)$ PREM14A Preliminary proxy statements relating to merger or acquisition Accession Number: 0001193125-24-096376 Act: 34 Size: 2 MB 网页链接
简介:Landos Biopharma, Inc.于2017年1月在特拉华州注册成立,是一家临床阶段的生物制药公司,致力于发现和开发针对自身免疫性疾病患者的口服治疗药物。他们的核心专长是开发针对新途径的免疫和新陈代谢治疗候选药物。 基于他们对细胞代谢途径在调节炎症反应中的作用的了解,他们旨在通过改变靶细胞的代谢过程来抑制这些炎症反应。
今开: | 昨收:22.93 |
最高: | 最低: |
涨停价: | 跌停价: |
总市值:71675534 |
Landos Biopharma(LABP)04-16 05:25
$Landos Biopharma(LABP)$ PREM14A Preliminary proxy statements relating to merger or acquisition Accession Number: 0001193125-24-096376 Act: 34 Size: 2 MB 网页链接
Landos Biopharma(LABP)04-11 04:55
$Landos Biopharma(LABP)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-091998 Act: 34 Size: 91 KB 网页链接
Landos Biopharma(LABP)05-24 04:55
$Landos Biopharma(LABP)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-24-146054 Act: 33 Size: 23 KB 网页链接
Landos Biopharma(LABP)05-24 05:55
$Landos Biopharma(LABP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014337 Size: 10 KB 网页链接
Landos Biopharma(LABP)05-24 00:15
$Landos Biopharma(LABP)$ 8-K Current report, item 5.07 Accession Number: 0001193125-24-145685 Act: 34 Size: 150 KB 网页链接
Landos Biopharma(LABP)05-24 04:55
$Landos Biopharma(LABP)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-24-146051 Act: 33 Size: 23 KB 网页链接
Landos Biopharma(LABP)05-24 05:55
$Landos Biopharma(LABP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014340 Size: 10 KB 网页链接
轻舟也可渡狂潮06-05 02:07
$Landos Biopharma(LABP)$ 只是生气不是我
Landos Biopharma(LABP)04-26 05:15
$Landos Biopharma(LABP)$ DEFM14A Definitive proxy statement relating to merger or acquisition Accession Number: 0001193125-24-114268 Act: 34 Size: 2 MB 网页链接
Landos Biopharma(LABP)05-24 05:55
$Landos Biopharma(LABP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014342 Size: 8 KB 网页链接
轻舟也可渡狂潮06-05 02:07
$Landos Biopharma(LABP)$ 只是生气不是我查看全文
不是蜜蜂2021-02-13 06:16
$Landos Biopharma(LABP)$ 是个做炎症和免疫系统疾病的公司,刚刚上市却已经有10几个在研项目,进入临床的都已经有4个,而且1/2/3期都有。公司预计今年还能申请3个INDs,2022-2025年再申请6个INDs,管线丰富得像个中型药厂。最近Perceptive,RTW都大量买入,而且买入的价格比现在的股价还高。感觉A...查看全文
chuminhua2021-01-16 16:00
1/15,Xontogeny的Landos Biopharma计划IPO,募集1亿美元。
Landos基于首席执行官Josep Bassaganya-Riera博士的工作,Josep Bassaganya-Riera博士是一位连续创业者和弗吉尼亚理工大学教授,他在2014年的一篇论文中概述了靶向羊毛硫氨酸合成酶C样蛋白2 (LANCL2) 途径影响免疫和炎症反应的潜力。...查看全文
艾伯維(AbbVie)(ABBV.US)將斥資高達2.12億美元收購藥物開發商Landos Biopharma(LABP.US),以擴大產品線,以治療與免疫系統相關的疾病。 Landos目前正在對其主要實驗藥物NX-13作中期研究,用於治療一種稱為潰... 网页链接
$Landos Biopharma(LABP)$ 15-12G Securities registration termination [Section 12(g)] Accession Number: 0001193125-24-152289 Act: 34 Size: 11 KB 网页链接
$Landos Biopharma(LABP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014342 Size: 8 KB 网页链接
$Landos Biopharma(LABP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014337 Size: 10 KB 网页链接
$Landos Biopharma(LABP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014340 Size: 10 KB 网页链接
$Landos Biopharma(LABP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014335 Size: 11 KB 网页链接
$Landos Biopharma(LABP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014334 Size: 11 KB 网页链接
$Landos Biopharma(LABP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014338 Size: 6 KB 网页链接
$Landos Biopharma(LABP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014336 Size: 10 KB 网页链接
$Landos Biopharma(LABP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014341 Size: 10 KB 网页链接
$Landos Biopharma(LABP)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-24-146048 Act: 33 Size: 23 KB 网页链接